JP2020512270A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512270A5
JP2020512270A5 JP2019515212A JP2019515212A JP2020512270A5 JP 2020512270 A5 JP2020512270 A5 JP 2020512270A5 JP 2019515212 A JP2019515212 A JP 2019515212A JP 2019515212 A JP2019515212 A JP 2019515212A JP 2020512270 A5 JP2020512270 A5 JP 2020512270A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
alkenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512270A (ja
JP7664680B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from KR1020180036895A external-priority patent/KR101938800B1/ko
Priority claimed from PCT/KR2018/003744 external-priority patent/WO2018182341A1/ko
Publication of JP2020512270A publication Critical patent/JP2020512270A/ja
Publication of JP2020512270A5 publication Critical patent/JP2020512270A5/ja
Priority to JP2023081396A priority Critical patent/JP2023113699A/ja
Application granted granted Critical
Publication of JP7664680B2 publication Critical patent/JP7664680B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515212A 2017-03-29 2018-03-29 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物 Active JP7664680B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023081396A JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2017-0039841 2017-03-29
KR20170039841 2017-03-29
KR1020180036895A KR101938800B1 (ko) 2017-03-29 2018-03-29 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
PCT/KR2018/003744 WO2018182341A1 (ko) 2017-03-29 2018-03-29 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
KR10-2018-0036895 2018-03-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023081396A Division JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物

Publications (3)

Publication Number Publication Date
JP2020512270A JP2020512270A (ja) 2020-04-23
JP2020512270A5 true JP2020512270A5 (cg-RX-API-DMAC7.html) 2021-05-13
JP7664680B2 JP7664680B2 (ja) 2025-04-18

Family

ID=63876096

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515212A Active JP7664680B2 (ja) 2017-03-29 2018-03-29 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
JP2023081396A Pending JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023081396A Pending JP2023113699A (ja) 2017-03-29 2023-05-17 ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物

Country Status (9)

Country Link
US (2) US11654197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3604311A4 (cg-RX-API-DMAC7.html)
JP (2) JP7664680B2 (cg-RX-API-DMAC7.html)
KR (4) KR101938800B1 (cg-RX-API-DMAC7.html)
CN (1) CN109790171B (cg-RX-API-DMAC7.html)
AU (1) AU2018246806B2 (cg-RX-API-DMAC7.html)
CA (1) CA3058360A1 (cg-RX-API-DMAC7.html)
IL (1) IL269535B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019011655A (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ, インク. ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
GB201803342D0 (en) * 2018-03-01 2018-04-18 Medimmune Ltd Methods
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20200084802A (ko) 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
US20220096641A1 (en) 2019-01-03 2022-03-31 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer compound with improved safety and use thereof
JP7664045B2 (ja) 2019-03-06 2025-04-17 リガケム バイオサイエンシズ, インク. ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
KR20210028544A (ko) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
BR112022013008A2 (pt) 2019-12-31 2022-09-06 Legochem Biosciences Inc Composto derivado de pirrolobenzodiazepina, conjugado de derivado-ligante de pirrolobenzodiazepina, e, composição farmacêutica e método para prevenção ou tratamento de doença proliferativa
CA3213985A1 (en) 2021-03-30 2022-10-06 Chang Sik Park Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
GB202203070D0 (en) * 2022-03-04 2022-04-20 Iksuda Therapeutics Ltd Anti-canag antibody conjugate
CN115429890B (zh) * 2022-08-04 2024-05-24 辽宁键凯科技有限公司 一种缀合物及用其制备的抗体药物偶联物
CN115772163B (zh) * 2022-12-09 2025-07-22 中国科学院成都生物研究所 吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用
EP4389152A1 (en) 2022-12-23 2024-06-26 Synaffix B.V. Conjugates of pbd prodrugs
AU2024224138A1 (en) * 2023-02-22 2025-08-14 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2026025083A1 (en) * 2024-07-25 2026-01-29 The General Hospital Corporation Localized in vivo prodrug activation using radioisotopes
CN119798218A (zh) * 2024-12-31 2025-04-11 南京优氟医药科技有限公司 一种e3酶配体-连接链复合物及其制备方法

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112739A (en) 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
DK0795334T3 (da) 1996-03-12 2006-06-06 Sanofi Aventis Deutschland Nye prodrugs til behandling af tumorer og betændelsessygdomme
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
EP0941120A4 (en) 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999057301A1 (en) 1998-04-30 1999-11-11 Maruha Corporation Compounds having glucuronic acid derivatives and glucosamine derivatives in the structure, process for producing the same and utilization thereof
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
JP2006510626A (ja) 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
CA2578131A1 (en) 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
EP1850849A2 (en) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
CN101287500A (zh) 2005-08-19 2008-10-15 恩多塞特公司 多药物配体缀合物
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2008034120A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
ZA200902161B (en) 2006-10-27 2010-06-30 Genentech Inc Antiobodies and immunoconjugates and uses therefor
WO2008056833A1 (en) 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
JP5404624B2 (ja) * 2007-08-01 2014-02-05 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ[2,1−c][1,4]ベンゾジアゼピン−グリコシドプロドラッグ
BRPI0818780A2 (pt) 2007-10-19 2015-04-22 Genentech Inc Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
WO2009116670A1 (ja) 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
KR101606219B1 (ko) 2008-03-24 2016-03-24 4에스체 악티엔게젤샤프트 신규 치환된 이미다조퀴놀린
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US9353140B2 (en) 2009-11-25 2016-05-31 Academia Sinica BQC-G, a tumor-selective anti-cancer prodrug
KR20110075542A (ko) 2009-12-28 2011-07-06 주식회사 효성 연료전지 시스템의 워터트랩 장치
MX368648B (es) 2010-04-15 2019-10-09 Seattle Genetics Inc Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas.
PT2528625E (pt) * 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
FR2960153B1 (fr) 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
US9591882B2 (en) 2010-08-05 2017-03-14 Robert LaGrand Duffin Absorbent sleeve
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
KR20120107741A (ko) 2011-03-22 2012-10-04 한국생명공학연구원 패혈증 단백질 치료제의 효능 분석 및 스크리닝 방법
WO2012138102A2 (ko) 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
KR101461706B1 (ko) 2011-04-04 2014-11-18 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
CN103502990A (zh) 2011-04-29 2014-01-08 惠普发展公司,有限责任合伙企业 用于事件的内存中处理的系统和方法
DK2707031T3 (da) 2011-05-08 2019-10-07 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP2800586A1 (en) 2012-01-03 2014-11-12 Invictus Oncology Pvt. Ltd. Ligand-targeted molecules and methods thereof
IN2014MN02092A (cg-RX-API-DMAC7.html) 2012-04-30 2015-09-04 Spirogen Sarl
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
AU2013366493B2 (en) * 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2687439T3 (es) * 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
HK1219044A1 (zh) 2013-03-15 2017-03-24 艾伯维德国有限责任两合公司 抗egfr抗体药物偶联物制剂
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015052533A1 (en) * 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
ES2729643T3 (es) 2013-11-26 2019-11-05 Novartis Ag Métodos para la conjugación de oxima con polipéptidos modificados con cetona
CN105813653B (zh) 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
HRP20241124T1 (hr) 2014-09-11 2024-11-22 Seagen Inc. Ciljana isporuka lijekovitih tvari koje sadrže tercijarni amin
EP3211638B1 (en) 2014-10-24 2023-11-29 Sony Interactive Entertainment Inc. Control device, control method, program and information storage medium
WO2016063595A1 (ja) 2014-10-24 2016-04-28 ソニー株式会社 画像処理装置、画像処理方法及びプログラム
JP2018502839A (ja) 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート
KR20160080832A (ko) 2014-12-29 2016-07-08 주식회사 레고켐 바이오사이언스 리피바디 유도체-약물 복합체, 그 제조방법 및 용도
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
CN114716506A (zh) 2015-01-30 2022-07-08 苏特罗生物制药公司 用于偶联和治疗的哈米特林(hemiasterlin)衍生物
WO2016142768A1 (en) 2015-03-10 2016-09-15 Eureka Therapeutics, Inc. Ror2 antibody
HK1253507A1 (zh) 2015-05-18 2019-06-21 Eureka Therapeutics, Inc. 抗 ror1 抗体
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
SG11201803054UA (en) 2015-10-13 2018-05-30 Eureka Therapeutics Inc Antibody agents specific for human cd19 and uses thereof
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
RU2651776C2 (ru) 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
MX2018008926A (es) 2016-01-20 2019-01-10 Scripps Research Inst Composiciones de anticuerpo contra ror1 y métodos relacionados.
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
SG10201900628RA (en) 2016-04-07 2019-02-27 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
CA3020873A1 (en) 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3040812A1 (en) 2016-11-04 2018-05-11 Novimmune Sa Anti-cd19 antibodies and methods of use thereof
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
US20200338210A1 (en) 2016-12-22 2020-10-29 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
WO2018146199A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2018182341A1 (ko) 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ, インク. ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
TWI804499B (zh) 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
KR20190018400A (ko) 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
WO2019050362A2 (ko) 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN119219654A (zh) 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
EP3802534B1 (en) 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2019243825A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Small molecule modulators of human sting, conjugates and therapeutic applications
CN110903395A (zh) 2018-09-14 2020-03-24 四川科伦博泰生物医药股份有限公司 抗体、偶联物及其制备方法和用途
CN113348181A (zh) 2018-10-31 2021-09-03 诺华股份有限公司 包含sting激动剂的dc-sign抗体缀合物
KR20200084802A (ko) 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
JP7664045B2 (ja) 2019-03-06 2025-04-17 リガケム バイオサイエンシズ, インク. ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
MX2021015188A (es) 2019-06-12 2022-01-18 Ryvu Therapeutics S A Moduladores de nueva generacion del estimulador de genes de interferon (sting).
DK4004002T3 (da) 2019-07-22 2024-09-30 Lupin Ltd Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed
KR20220056176A (ko) 2019-08-02 2022-05-04 메르사나 테라퓨틱스, 인코포레이티드 암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021046426A1 (en) 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
US11184191B1 (en) 2019-09-12 2021-11-23 Trend Micro Incorporated Inspection of network traffic on accelerated platforms
EP4228701A1 (en) 2020-10-19 2023-08-23 Vaccitech North America, Inc. Star polymer drug conjugates
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof
EP4277904A1 (en) 2021-01-15 2023-11-22 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2022177307A1 (ko) 2021-02-17 2022-08-25 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
CA3213985A1 (en) 2021-03-30 2022-10-06 Chang Sik Park Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
US20250090681A1 (en) 2021-06-03 2025-03-20 Orum Therapeutics, Inc. Neodegrader conjugates
US20250313557A1 (en) 2022-04-29 2025-10-09 Ligachem Biosciences Inc. Imidazo[4,5-c]pyridine derivative compounds as tlr7/8 modulators
KR20250120285A (ko) 2022-11-08 2025-08-08 주식회사 리가켐바이오사이언스 Sting 작용제
JP2026510495A (ja) 2023-03-10 2026-04-07 リガケム バイオサイエンシズ, インク. ヒトl1camに対する抗体を含む抗体-薬物コンジュゲートおよびその使用

Similar Documents

Publication Publication Date Title
TW505636B (en) Polar-substituted hydrocarbons
JP2014534200A5 (cg-RX-API-DMAC7.html)
JP3749253B2 (ja) 環状ポリアミン
IL312845B1 (en) Extacan derivatives, charge-linkers, and their conjugates
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
JP2022538228A5 (cg-RX-API-DMAC7.html)
JP2022510505A5 (cg-RX-API-DMAC7.html)
JP2019535746A5 (cg-RX-API-DMAC7.html)
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2009515890A5 (cg-RX-API-DMAC7.html)
SI2300013T1 (en) Phosphorus derivatives as kinase inhibitors
WO2016065139A1 (en) 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
WO2014121033A1 (en) Soluble complexes of drug analogs and albumin
DE602006006199D1 (de) 4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
US12371417B2 (en) Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties
JP2018511628A5 (cg-RX-API-DMAC7.html)
WO2015200837A1 (en) Abiraterone derivatives and non-covalent complexes with albumin
JP2022546110A5 (cg-RX-API-DMAC7.html)
RU2007143507A (ru) Производные фенилацетилена, обладающие сродством к рецептору mglur 5
AR045811A1 (es) 5- arilpirimidinas como agentes ainticancerigenos
CZ286180B6 (cs) 6,9-bis(Substituované amino)benzo/g/isochinolin-5 10-diony
WO2023204631A1 (ko) Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
EP3400210A2 (fr) Composés"multi-cibles"à activité inhibitrice des histone-désacétylases et de la polymérisation de la tubuline pour son utilisation dans le traitement du cancer
JP2019508391A5 (cg-RX-API-DMAC7.html)
US10927088B2 (en) Thymoquinone derivatives for treatment of cancer